Midostaurin in Treating Older Patients With Mutated Acute Myeloid Leukemia Post-Transplant
Trial ID or NCT#
NCT02723435
Status
NOT RECRUITING
Purpose
This phase 2 trial studies the side effects and how well midostaurin works in treating older patients with acute myeloid leukemia with change in genetic material post-hematopoietic cell transplantation. Midostaruin may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving midostaruin post-transplant may improve patient outcomes.
Official Title
An Open-Label Extension Study of Post-Transplant Maintenance Midostaurin (PKC412) in Elderly Patients (Age ≥ 60 Years) With FLT3-ITD/TKD Mutated AML Who Previously Received Midostaurin and Decitabine as Part of Study HEMAML0022 / CPKC412AUS27T
Eligibility Criteria
Ages Eligible for Study: Older than 60 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: Yes
Exclusion Criteria:
Investigator(s)
Contact us to find out if this trial is right for you.
Contact
Jack Taw
650-723-2781
View on